Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults

Infection and Immunity

Volumn 69, Issue 2, 2001, Pages 988-995

  Kotloff, K L ^a   Wasserman, S S ^a   Losonsky, G A ^a   Thomas W , Jr ^a   Nichols, R ^a   Edelman, R ^a   Bridwell, M ^a   Monath, T P ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VACCINE;

ABDOMINAL PAIN; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOSPITAL INFECTION; HUMAN; IMMUNOGENICITY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; TOXOIDS;

EID: 0035145510     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.69.2.988-995.2001     Document Type: Article

References (39)

1. Value of routine stool cultures in hospitalized patients with diarrhea
2. Invasive pneumococcal infections: Incidence, predisposing factors, and prognosis
3. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A
4. Nosocomial infections in human immunodeficiency virus-infected patients in a long-term-care setting
5. Active and passive immunization to protect against antibiotic associated caecitis in hamsters
6. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters
7. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of the cultured human
8. Epidemiology of community-acquired Clostridium difficile-associated diarrhea
9. Clostridium difficile-associated diarrhea
10. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden
11. Clostridium difficile colitis
12. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding
13. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins
14. The impact of Clostridium difficile on a surgical service: A prospective study of 374 patients
15. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters
16. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection
17. Clostridium difficile: Clinical disease and diagnosis
18. Lack of association between Clostridium difficile toxin and diarrhea in infants
19. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
20. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
21. A retrospective cohort study of nosocomial diarrhea as a risk factor for nosocomial infection
22. Systemic and mucosal immune responses to rhesus rotavirus vaccine MMU 18006
23. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate
24. Epidemiology of infectious and iatrogenic nosocomial diarrhea in a cohort of general medicine patients
25. Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics
26. Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy
27. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro
28. Antibiotic-associated diarrhoea. A costly problem
29. Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia
30. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis
31. Clinical impact and associated costs of Clostridium difficile-associated disease
32. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters
33. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei
34. Serum antibody response to toxins A and B of Clostridium difficile
35. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations
36. Gamma globulin administration in relapsing Clostridium difficile-induced pseudomembranous colitis with a defective antibody response to toxin A
37. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
38. Cleaning up Clostridium difficile infection
39. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies